Literature DB >> 17915572

Pharmacological and nutritional treatment trials in McArdle disease.

R M Quinlivan1, R J Beynon.   

Abstract

A systematic review of evidence for randomised controlled trials using pharmacologic and nutritional therapies in McArdle disease was undertaken. Primary outcome measures included any objective assessment of exercise endurance. Secondary outcome measures included changes in metabolic parameters, subjective measures such as quality of life scores and adverse outcomes. Ten randomised controlled trials were identified. Two trials low dose creatine (60 mg/kg/day) and oral sucrose 75 g prior to exercise demonstrated a positive effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915572      PMCID: PMC2949313     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  21 in total

1.  The effect of oral sucrose on exercise tolerance in patients with McArdle's disease.

Authors:  John Vissing; Ronald G Haller
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

2.  Long-term creatine intake is beneficial to muscle performance during resistance training.

Authors:  K Vandenberghe; M Goris; P Van Hecke; M Van Leemputte; L Vangerven; P Hespel
Journal:  J Appl Physiol (1985)       Date:  1997-12

3.  Beneficial effects of dantrolene sodium in exercise-induced muscle pains: calcium mediated?

Authors:  T Bertorini; G Palmieri; S Bhattacharya
Journal:  Lancet       Date:  1982-03-13       Impact factor: 79.321

4.  Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study.

Authors:  Matthias Vorgerd; Jochen Zange; Rudolf Kley; T Grehl; Anika Hüsing; Matthias Jäger; Klaus Müller; Rolf Schröder; Wilhelm Mortier; Klaus Fabian; Jean-Pierre Malin; Alwin Luttmann
Journal:  Arch Neurol       Date:  2002-01

5.  Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial.

Authors:  M Vorgerd; T Grehl; M Jager; K Muller; G Freitag; T Patzold; N Bruns; K Fabian; M Tegenthoff; W Mortier; A Luttmann; J Zange; J P Malin
Journal:  Arch Neurol       Date:  2000-07

6.  Sympathetic activation in exercise is not dependent on muscle acidosis. Direct evidence from studies in metabolic myopathies.

Authors:  J Vissing; S F Vissing; D A MacLean; B Saltin; B Quistorff; R G Haller
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

7.  Low muscle levels of pyridoxine in McArdle's syndrome.

Authors:  R G Haller; W B Dempsey; H Feit; J D Cook; J P Knochel
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

8.  Spontaneous "second wind" and glucose-induced second "second wind" in McArdle disease: oxidative mechanisms.

Authors:  Ronald G Haller; John Vissing
Journal:  Arch Neurol       Date:  2002-09

Review 9.  Pharmacological and nutritional treatment for McArdle's disease (Glycogen Storage Disease type V).

Authors:  R Quinlivan; R J Beynon
Journal:  Cochrane Database Syst Rev       Date:  2004

10.  Oral branched-chain amino acids do not improve exercise capacity in McArdle disease.

Authors:  D MacLean; J Vissing; S F Vissing; R G Haller
Journal:  Neurology       Date:  1998-11       Impact factor: 9.910

View more
  3 in total

1.  Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  A Manta; S Spendiff; H Lochmüller; R Thompson
Journal:  J Neuromuscul Dis       Date:  2021

2.  Metabolic myopathy presenting with polyarteritis nodosa: a case report.

Authors:  Sahana Vishwanath; Mishal Abdullah; Amro Elbalkhi; Julian L Ambrus
Journal:  J Med Case Rep       Date:  2011-06-30

Review 3.  McArdle Disease: New Insights into Its Underlying Molecular Mechanisms.

Authors:  Francisco Llavero; Alazne Arrazola Sastre; Miriam Luque Montoro; Patricia Gálvez; Hadriano M Lacerda; Luis A Parada; José Luis Zugaza
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.